As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Acrivon Therapeutics, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 28.8%. 7 filings are on record since August 13, 2025 (Schedule 13D/A, April 23, 2026).
Sell to companies like Acrivon Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sands Capital Life Sciences Pulse Fund II, L.P. · Sole voting: 0 · Shared voting: 2,289,271 · Sole dispositive: 0 · Shared dispositive: 2,289,271 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Citadel Advisors LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 12,284,906 · Sole dispositive: 0 · Shared dispositive: 12,284,906 · SCHEDULE 13D/A, 2026-04-23
- · Holder: RA Capital Management, L.P. · Percent: 21.6% · SCHEDULE 13D/A
- · Holder: Kenneth Griffin · Percent: 5.5% · SCHEDULE 13G
Acrivon Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 28.8% | 12,284,906 | SCHEDULE 13D/A, 2026-04-23 | 2026-04-22 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 5.3% | 2,289,271 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Citadel Advisors LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Acrivon Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Acrivon Therapeutics, Inc. and the records around it.
Acrivon Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Inhibikase Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026), Beta Bionics, Inc. (Aug 2025)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Acrivon Therapeutics, Inc.
Get an email when Acrivon Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Acrivon Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Acrivon Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acrivon Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 12,284,906 | 0 | 12,284,906 | SCHEDULE 13D/A, 2026-04-23 |
| Peter Kolchinsky | 0 | 12,284,906 | 0 | 12,284,906 | SCHEDULE 13D/A, 2026-04-23 |
| Rajeev Shah | 0 | 12,284,906 | 0 | 12,284,906 | SCHEDULE 13D/A, 2026-04-23 |
| RA Capital Healthcare Fund, L.P. | 0 | 11,803,094 | 0 | 11,803,094 | SCHEDULE 13D/A, 2026-04-23 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 0 | 2,289,271 | 0 | 2,289,271 | SCHEDULE 13G/A, 2026-08-13 |
| Sands Capital Alternatives, LLC | 0 | 2,289,271 | 0 | 2,289,271 | SCHEDULE 13G/A, 2026-08-13 |
| Sands Frank M. | 0 | 2,289,271 | 0 | 2,289,271 | SCHEDULE 13G/A, 2026-08-13 |
| Citadel Advisors LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Citadel Advisors Holdings LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Citadel GP LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Citadel Securities LLC | 0 | 13 | 0 | 13 | SCHEDULE 13G/A, 2026-05-15 |
| Citadel Securities Group LP | 0 | 13 | 0 | 13 | SCHEDULE 13G/A, 2026-05-15 |
| Citadel Securities GP LLC | 0 | 13 | 0 | 13 | SCHEDULE 13G/A, 2026-05-15 |
| Kenneth Griffin | 0 | 13 | 0 | 13 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Acrivon Therapeutics, Inc. by CUSIP 004890109 and gives its principal executive office as 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA 02472 (SCHEDULE 13G/A, 2026-08-13).
Source of funds (Item 3)
Item 3 of the Statement is hereby amended and supplemented as follows: On April 22, 2026, the Fund purchased 3,888,888 shares of common stock in an at-the-market offering by the Issuer (the "ATM Offering") at a price of $1.80 per share, for total consideration of $6,999,998.40. The purchase was for cash and was funded by the working capital of the Fund.RA Capital Management, L.P., SCHEDULE 13D/A, 2026-04-23
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | SCHEDULE 13G/A |
| 2025-11-14 | Citadel Advisors LLC | 4.9% | SCHEDULE 13G/A |
| 2025-11-21 | Kenneth Griffin | 5.5% | SCHEDULE 13G |
| 2026-03-23 | RA Capital Management, L.P. | 21.6% | SCHEDULE 13D/A |
| 2026-04-23 | RA Capital Management, L.P. | 28.8% | SCHEDULE 13D/A |
| 2026-05-15 | Citadel Advisors LLC | 0% | SCHEDULE 13G/A |
| 2026-08-13 | Sands Capital Life Sciences Pulse Fund II, L.P. | 5.3% | SCHEDULE 13G/A |
Questions about who owns Acrivon Therapeutics, Inc.
Who owns Acrivon Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Acrivon Therapeutics, Inc.: RA Capital Management, L.P. (28.8%, Schedule 13D/A, filed 2026-04-23) and Sands Capital Life Sciences Pulse Fund II, L.P. (5.3%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Acrivon Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Acrivon Therapeutics, Inc. on this page are RA Capital Management, L.P. (28.8%) and Sands Capital Life Sciences Pulse Fund II, L.P. (5.3%).
When did RA Capital Management, L.P. buy into Acrivon Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-03-23, reporting 21.6%; its latest, Schedule 13D/A filed 2026-04-23, reports 28.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Acrivon Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.